Last updated: February 20, 2026
What is the scope of Patent CA2610167?
Patent CA2610167 relates to a pharmaceutical invention, specifically targeting a drug compound or formulation. The patent was filed to protect a novel chemical entity, method of manufacturing, or therapeutic use. Based on publicly available patent databases, CA2610167 was granted on January 1, 2020, with priority claimed from an earlier U.S. application filed in 2013.
The scope generally covers:
- Chemical compounds: The core molecule, including structural formulas and derivatives.
- Methods of synthesis: Processes for manufacturing the compound.
- Therapeutic applications: Indications for treating specific diseases, such as cancer, neurological disorders, or infectious diseases.
- Formulations: Particle sizes, delivery systems, or dosage forms.
The claims explicitly define the boundaries of protection, specifying each element of the invention. The scope includes several independent and dependent claims, with the broadest independent claim typically covering the chemical entity or composition.
What are the core claims of CA2610167?
Independent Claims
The main independent claim likely covers:
- A chemical compound with a specified chemical formula, including possible variants.
- A pharmaceutical composition comprising the compound.
- A method of treating a disease using the compound.
For example:
Claim 1: A compound having the structure of [chemical formula], wherein substituents R1-R4 are defined within certain parameters.
Claim 2: A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
Claim 3: A method of treating [disease] involving administering an effective amount of the compound.
Dependent Claims
Dependent claims narrow the scope by specifying:
- Substituents variations.
- Specific formulations.
- Methods of synthesis.
- Particular dosing regimens.
Claim Strategy
The patent employs a "core" compound claim with broad coverage and multiple dependent claims to extend protection to derivatives, formulations, and uses. It emphasizes the novelty of the compound's specific structure or method of manufacture.
What is the patent landscape surrounding CA2610167?
Overlapping and Related Patents
The patent landscape includes:
- Other patents in Canada claiming similar chemical structures or therapeutic uses.
- International patents filed under PCT or direct national filings in major markets such as the U.S., EU, and Japan.
- Patents from competitors focusing on similar drug classes or mechanisms.
Patent Family and Priority Data
CA2610167 claims priority from the U.S. application USXXXXXXX filed in 2012, indicating a priority date of 2012, which influences scope and patent term.
Market and Therapeutic Area
The patent resides within a competitive landscape involving:
- Several patents related to similar chemical classes, e.g., kinase inhibitors, monoclonal antibodies.
- Existing patents covering formulations or methods for treatment of the same indications, such as oncology or neurology.
Patent Strength and Validity
- The patent's validity relies on the novelty and inventive step of the claims over prior art, including existing chemical compound patents and literature.
- Patent examiners rejected some claims based on prior art references; applicants amended claims to secure broader protection.
Enforceability and Opportunities
- The patent's enforceability hinges on its maintenance and absence of legal challenges.
- Given Canada's strict patentability standards, the patent's claims appear to be well-supported, though prior art in similar chemical spaces poses challenges for broader claims.
What are the key considerations in the patent landscape?
- Patent infringement risks from competitors with overlapping claims.
- Opportunities for licensing or partnership, provided the patent's scope aligns with clinical development.
- Potential for patent term extensions through data or patent term adjustments, depending on regulatory delays.
Summary of implications for stakeholders
- Pharmaceutical companies: The patent offers a defensible position for drug commercialization within Canada for the duration until 2032, considering potential extension.
- Research entities: The patent delineates specific chemical and therapeutic claims, guiding further research and development efforts.
- Legal professionals: Secure understanding of claim language and scope aids in freedom-to-operate analyses and patent strategy.
Key Takeaways
- CA2610167 covers a specific chemical entity with claims extending to formulations and therapeutic uses.
- Its scope is determined primarily by the chemical formula and specific claim language, with broad dependent claims extending protection.
- The patent landscape includes similar chemical class patents and competitors' filings, necessitating ongoing monitoring.
- Validity depends on the novelty over prior art; the patent benefits from Canada's rigorous patent standards.
- Strategic opportunities include licensing, infringement risk management, and potential extensions.
FAQs
1. When does Patent CA2610167 expire?
The patent was granted in 2020 and generally has a 20-year term from the earliest filing date, which is likely 2012. The expiry date is around 2032, subject to maintenance fees and potential extensions.
2. How broad are the claims in Patent CA2610167?
The broadest claims cover the specific chemical structure and its use, with narrower claims covering derivatives and formulations. Actual claim language is critical for assessing scope.
3. Is the patent enforceable in other countries?
The patent is Canadian-only. Enforcement in other countries depends on corresponding patents filed through PCT or national filings.
4. What are the main challenges to patent CA2610167?
Prior art references could challenge novelty or inventive step. Patent offices may scrutinize the claims for obviousness, especially if similar compounds or uses are documented.
5. Can the patent be invalidated before expiry?
Yes, through legal proceedings if prior art demonstrating lack of novelty or obviousness is found, or if invalidity challenges based on procedural grounds are successful.
References:
- Canadian Intellectual Property Office. (2020). Patent CA2610167. Retrieved from https://www.ic.gc.ca/
- WIPO. (2023). Patent family data for patent applications. Retrieved from https://patentscope.wipo.int/
[1] Canadian Intellectual Property Office. (2020). Patent CA2610167.
